Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2
1(50.0%)
Phase 3
1(50.0%)
2Total
Phase 2(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06508931Phase 2Recruiting

Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms

Role: collaborator

NCT05046613Recruiting

Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant

Role: collaborator

NCT06052059Phase 3Active Not Recruiting

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

Role: collaborator

NCT03664648Unknown

DV2-HBV-27: Observational Pregnancy Registry

Role: collaborator

All 4 trials loaded